
Blinatumomab integration led to high complete response and minimal residual disease-negativity rates, especially in patients over 40 and Philadelphia chromosome-positive cases.

Blinatumomab integration led to high complete response and minimal residual disease-negativity rates, especially in patients over 40 and Philadelphia chromosome-positive cases.

Final analysis from KEYNOTE-585 revealed that event-free survival (EFS) was not significantly improved.

The FDA approved adagrasib with cetuximab for KRAS G12C-mutated CRC and an AI-driven mortality models improve palliative care. We also cover data on datopotamab deruxtecan showing promise in HER2-low breast cancer, zanubrutinib plus venetoclax achieving 100% ORR in high-risk CLL/SLL, and an overview of treatments HER2-targeted treatments highlighting T-DXd in CNS involvement.

Vikram Narayan, MD, discussed the durable clinical activity observed with nadofaragene firadenovec in the CS-003 trial for patients with non-muscle invasive bladder cancer.

Zanubrutinib treatment resulted in £599,000 cost savings and 3.7 QALY savings compared with acalabrutinib for 1000 hypothetical patients.

The latest research on circulating tumor DNA and circulating tumor cells isolated through liquid biopsies is revolutionizing cancer care by enabling early detection, treatment monitoring, and personalized medicine strategies.

The FDA approved Tepylute, a ready-to-dilute formulation of an existing treatment for breast and ovarian adenocarcinoma.

A phase 1/2a study is investigating the novel antibody-drug conjugate for the treatment of ovarian and non–small cell lung cancers.

Disease duration, thrombotic event history, elevated WBC count, HCT levels, and VAF are key predictors of polycythemia vera progression.

Douglas B. Johnson, MD, MSCI, offers a comprehensive exploration of the nuances for using neoadjuvant therapy, addressing various treatment combinations, along with recommendations for first-line systemic therapy.

Recent approvals herald novel strategies for addressing advanced or metastatic breast cancer with ESR1 mutations.

Patritumab deruxtecan has been issued a complete response letter to its biologics license application for the treatment for patients with advanced non-small cell lung cancer with EGFR mutations after prior treatment with 2 or more lines of therapy.

This FDA approval marks the first subcutaneous bispecific antibody to be approved in patients with relapsed/refractory follicular lymphoma.

An increased likelihood of response was also observed in patients who received no more than 3 lines of therapy prior to liso-cel in the TRANSCEND CLL 004 trial.

In certain patients, surgical omission, radiotherapy omission, and immunotherapy are being explored.

Ali Duffens, MD, discusses a study in which investigators assessed the mode of detection for breast cancer recurrence within an integrated health system by assessing the utility and outcomes of current surveillance guidelines recommended by the National Comprehensive Cancer Network.

Tanya Gupta, MD, highlighted the approved indications for antibody-drug conjugates in breast cancer, the efficacy data supporting their approvals, and ongoing studies to advance the space further.

In general, mutations can occur in several genes in cytologically normal AML cells, including NPM1, FLT3, CEBPA, MLL, NRAS.

CT-0525 has received a fast track designation from the FDA for the treatment of solid tumors that overexpress HER2.

Missak Haigentz, MD, discusses the impact of the results from the ADRIATIC study of durvalumab as consolidation treatment after concurrent chemoradiation for the treatment of patients with limited-stage small cell lung cancer.

Health care organizations face a growing wave of cyberattacks and must implement strong defenses to protect patient data and ensure operational continuity.

Secondary malignancies following CAR T-cell therapy have been a known risk, but an FDA investigation and call for labeling change have renewed interest.

Combining durvalumab with chemotherapy in the NIAGARA trial led to significant improvements in event-free survival and overall survival for patients with muscle-invasive bladder cancer.

Paula Rodríguez Otero, MD, PhD, discussed the deepening of response and minimal residual negativity during maintenance in the PERSEUS study for patients with multiple myeloma.

The debate on non-specific vs targeted therapies in oncology highlights the need for a balanced approach optimizing existing agents while developing biomarkers and precision medicine.

The FDA granted a rare pediatric disease designation to a promising new drug, SLS009, for the treatment of pediatric leukemia.

Mark A. Lewis, MD, discussed the growing excitement of using dostarlimab for the treatment of colorectal cancer and explored ways to maximize its potential.

Recent data, trials, approvals, and presentations during the 2024 American Urological Association Annual Meeting paint a positive treatment landscape for patients with metastatic and non–muscle-invasive bladder cancer.

Endometrial cancer scores 2 approvals, and PFS benefit is observed with amivantamab/chemotherapy in NSCLC. We also cover T-DXd efficacy in HER2 breast cancer with brain metastasis and the approval of repotrectinib for NTRK-positive solid tumors.

Nikhil Khushalani, MD, discussed a phase 3 study investigating fianlimab plus cemiplimab vs nivolumab and relatlimab for the treatment of patients with advanced melanoma.